Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001176309 XXXXXXXX LIVE 3 Ordinary Shares, par value NIS 5.00 per share 07/20/2026 false 0001643303 63008G203 Nano Dimension Ltd. 60 TOWER ROAD WALTHAM MA 02451 Avraham Gabay 972 25788763 1185 Avenue of the Americas, Third Floor New York NY 10036 0001176309 N Oramed Pharmaceuticals Inc. WC N DE 6879708.00 0.00 6879708.00 0.00 6879708.00 N 3.3 CO Ordinary Shares, par value NIS 5.00 per share Nano Dimension Ltd. 60 TOWER ROAD WALTHAM MA 02451 This Amendment No. 3 to Schedule 13D is filed by and on behalf of the Reporting Person to further amend the Schedule 13D related to the Ordinary Shares, par value NIS 5.00 per share (the "Ordinary Shares") of Nano Dimension Ltd. (the "Issuer"), initially filed with the U.S. Securities and Exchange Commission (the "SEC") on January 29, 2026, as amended by Amendment No. 1 to Schedule 13D that was filed by the Reporting Person with the SEC on February 19, 2026, and Amendment No. 2 to Schedule 13D that was filed by the Reporting Person with the SEC on June 17, 2026 (as amended, the "Schedule 13D"). Each capitalized term used and not defined herein shall have the meaning assigned to such term in the Schedule 13D. Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged. Item 3 is hereby amended and supplemented as follows: "In open market purchases on July 20, 2026, the Reporting Person expended an aggregate of approximately $1,258,000 (excluding commissions) to purchase call options referencing an aggregate of 8,200,000 Ordinary Shares. The funds used for the purchase of the securities reported in this Schedule 13D were derived from the general working capital of the Reporting Person." Item 5(a) is hereby amended and restated in its entirety as follows: "(a) The aggregate number and percentage of the class of securities identified pursuant to Item 1 beneficially owned by the Reporting Person is stated in Items 11 and 13 on the cover pages hereto. The percentage reported in Item 13 on the cover pages hereto is based upon 210,506,899 Ordinary Shares of the Issuer outstanding as of June 23, 2026, according to the Schedule 14A filed by the Issuer with the SEC on June 30, 2026." Item 5(b) is hereby amended and restated in its entirety as follows: "(b) Number of shares as to which the Reporting Person has (i) sole power to vote or direct the vote: See Item 7 on the cover page(s) hereto. (ii) shared power to vote or direct the vote See Item 8 on the cover page(s) hereto. (iii) sole power to dispose or to direct the disposition of: See Item 9 on the cover page(s) hereto. (iv) shared power to dispose or to direct the disposition of: See Item 10 on the cover page(s) hereto." Item 5(c) is hereby amended and restated in its entirety as follows: "(c) On July 20, 2026, pursuant to a block sale, the Reporting Person sold 8,200,000 Ordinary Shares at a price per share of $1.55. Other than the foregoing and as set forth in Item 3 and Item 6 of this Schedule 13D, there have been no transactions in the class of securities reported on that were effected by the Reporting Person during the past sixty days or since the most recent filing of Schedule 13D, whichever is less." Item 5(e) is hereby amended and restated in its entirety as follows: "(e) The Reporting Person ceased to beneficially own more than five percent of the outstanding Ordinary Shares on July 20, 2026." Item 6 is hereby amended and supplemented as follows: "The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference. On July 20, 2026, the Reporting Person engaged in the following transactions: (i) purchased call options referencing an aggregate of 1,350,000 Ordinary Shares, having an exercise price of $1.50 per Ordinary Share and expiring on August 21, 2026; (ii) purchased call options referencing an aggregate of 6,850,000 Ordinary Shares, having an exercise price of $2.00 per Ordinary Share and expiring on November 20, 2026; (iii) sold put options for an aggregate of approximately $44,999 (excluding commissions) referencing an aggregate of 4,500,000 Ordinary Shares, having an exercise price of $1.00 per Ordinary Share and expiring on August 21, 2026; and (iv) sold put options for an aggregate of approximately $102,998 (excluding commissions) referencing an aggregate of 3,700,000 Ordinary Shares, having an exercise price of $1.50 per Ordinary Share and expiring on August 21, 2026. Following these transactions, the Reporting Person is no longer a party to any options contracts with respect to the Ordinary Shares." Oramed Pharmaceuticals Inc. /s/ Avraham Gabay Avraham Gabay, Chief Financial Officer 07/22/2026